Trattamento delle lesioni cutanee, acute e croniche, mediante

More documents

Recommendations

Info

First author year study pub type base dati setting prospective condition comparatorresultsICERQALYresults CCother resultsfinancialsupportnoteMouës CM 2005CostanalysisresearcharticleRCT hospital HCS chronic garze umide nocost / patient: 2235€TNP vs 2565€ MWTnonedeclaredPhilbeck TE 1999 CEAresearcharticlemedicare-Trial byferrell et al93homeHCSpressureulcerscost / ferita guarita: 14546$ TNP vs23465 MWT?abstractedas reportedby Neubauer2003Vuerstaek 2006 cost analysisresearcharticleRCT hospital HCSchronicleg ulceridrocolloidialginatidominantecost per hospitalised ulcer 25% to30less for TNPKCIWeinberggroup1999Williams 2001case studywith costanalysisHTA report medicare home HCS chronicHTA reportmedicare+otherinsurancedatacost analysiscostconsequenceinpatient,home,longtermcareHCSCosto per 8 o + sett.Tratt: 23837$ TNP vs25762 MWTsaving per patientper year: 1623$KCIKCIabstractedas reportedby Neubauer2003abstractedas reportedby Neubauer2003BaharestaniMM.2004conferenceabstractLangley-Hawthorne C2004conferenceabstractNiezgoda JA. 2005conferenceabstract83
Bibliografia degli studi inclusiApelqvist J, Armstrong DG, Lavery LA, Boulton AJM. Resource utilization and economic costs ofcare based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabeticfoot wounds. The American Journal of Surgery (2008) 195, 782–788Baharestani MM. Negative pressure wound therapy: an examination of cost-effectiveness. OstomyWound Manage 2004; 50 (11A-Suppl): 29S–33S.Braakenburg A, Obdeijn MC, Feitz R, van Rooij IA, van Griethuysen AJ, Klinkenbijl JH. Theclinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the managementof <strong>acute</strong> and chronic wounds: a randomized controlled trial. Plastic and reconstructive surgery. 2006Aug;118(2):390-7.de Leon JM, Barnes S, Nagel M, Fudge M, Lucius A, Garcia B. Cost-effectiveness of negativepressure wound therapy for postsurgical patients in long-term <strong>acute</strong> care. Adv Skin Wound Care.2009 Mar;22(3):122-7.Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasmagel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care.2008 Dec;21(12):568-75.Flack S, Apelqvist J, Keith M, Trueman P, Williams D. An economic evaluation of VAC therapycompared with wound dressings in the treatment of diabetic foot ulcers. J Wound Care. 2008Feb;17(2):71-8.Langley-Hawthorne C. Economics of negative pressure wound therapy. Ostomy Wound Manage.2004 Apr;50(4A Suppl):35-7.Mody GN, Nirmal IA, Duraisamy S, Perakath B. A blinded, prospective, randomized controlledtrial of topical negative pressure wound closure in India. Ostomy Wound Manage. 2008Dec;54(12):36-46.Mokhtari A, Gren JS, Nilsson J, Gustafsson R, Malmsjo M, Ingemansson R. The cost of vacuumassistedclosure therapy in treatment of deep sternal wound infection. Scandinavian CardiovascularJournal. 2008; 42: 85_89Mouës CM, van den Bemd GJ, Meerding WJ, Hovius SE. An economic evaluation of the use ofTNP on full-thickness wounds. J Wound Care. 2005 May;14(5):224-7.Neubauer G, Ujlaky R. The cost-effectiveness of topical negative pressure versus other woundhealingtherapies. J Wound Care. 2003 Nov;12(10):392-3.Niezgoda JA. The economic value of negative pressure wound therapy. Ostomy Wound Manage.2005 Feb;51(2A Suppl):44S-47S.84
Page 1 and 2:
LAZIOSANITÀAGENZIA DI SANITÀ PUBB
Page 3 and 4:
INDICEEXECUTIVE SUMMARY............
Page 5 and 6:
esistono protocolli standard ampiam
Page 7 and 8:
20,15;-2,88]) e nell’aumentare la
Page 9 and 10:
• Giorgio Guarnera (IRCCS IDI, Ro
Page 11 and 12:
2.1. Epidemiologia2.1.1. Classifica
Page 13 and 14:
Tabella 1. Classificazione delle ti
Page 15 and 16:
Il setting del trattamento può var
Page 17 and 18:
3. SCOPO3.0. Rassegna delle Linee G
Page 19 and 20:
3.3. Costo efficaciaNon essendo in
Page 21 and 22:
4. RISULTATI4.0. Rassegna delle Lin
Page 23 and 24:
Medical Advisory Secretariat.Negati
Page 25 and 26:
2) Allarme: contenitore dei fluidi
Page 27 and 28:
La FDA fornisce alcune raccomandazi
Page 29 and 30:
− qualità della vita− riduzion
Page 31 and 32:
• Stannard 2006 I e Stannard 2006
Page 33 and 34: McCallon 2000 (lesioni croniche) ri
Page 35 and 36: Tempo alla guarigione completa (Ana
Page 37 and 38: TotaleL'effetto overall non è stat
Page 39 and 40: Aumento batterico prima/dopo (Anali
Page 41 and 42: Analisi per ulcere da pressioneI so
Page 43 and 44: Mouës 2004MetodiPartecipantiRCT; s
Page 45 and 46: % mediana successi innesti cutanei:
Page 47 and 48: Braakenburg 2006MetodiPartecipantiI
Page 49 and 50: Joseph 2000 (Cochrane 07)MetodiRCT;
Page 51 and 52: Blume 2008MetodiPartecipantiInterve
Page 53 and 54: Bee 2008MetodiPartecipantiIntervent
Page 55 and 56: Llanos S, Danilla S, Barraza C, Arm
Page 57 and 58: Figura 3 (Analisi 1.3) Confronto 1:
Page 59 and 60: Figura 7 (Analisi 1.7) Confronto 1:
Page 61 and 62: Figura 11 (Analisi 2.2) Confronto 2
Page 81 and 82: nelle due review. Entrambi gli stud
Page 83: Tabella 4. Caratteristiche degli st
Page 87 and 88: 4.3.2 Rilevazione e analisi dei cos
Page 89 and 90: VocicostoTrattamento convaccostiTra
Page 91 and 92: Accettabilità da parte degli opera
Page 93 and 94: 4.5. Impatto eticoDurante l’anali
Page 95 and 96: Strumentazione e applicazione Renas
show all

Trattamento delle lesioni cutanee, acute e croniche, mediante

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?